Oculis Holding AG (OCS) Shares Outstanding (2020 - 2026)
Oculis Holding AG (OCS) posted quarterly Shares Outstanding (Entity) of $45.7 million for Q4 2025, up 29.29% year-over-year from $35.3 million in Q4 2024, and little changed quarter-over-quarter from $45.8 million in Q3 2025.
Analysis
Oculis Holding AG (OCS) Shares Outstanding (2020 - 2026) Analysis & Trends
Oculis Holding AG's Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $45.7 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 29.29% year-over-year to $45.7 million; the TTM figure through Dec 2025 stood at $45.7 million (up 29.29% YoY), while the FY2025 annual figure was $45.7 million, up 29.29% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $45.7 million, roughly flat from $45.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $45.8 million in Q3 2025, with the low at $2.4 million in Q4 2021.
- The 5-year median for Shares Outstanding (Entity) is $31.8 million (2023), against an average of $25.8 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) grew 7.63% in 2022, then soared 949.52% in 2023.
- Oculis Holding AG's Shares Outstanding (Entity) stood at $2.4 million in 2021, then grew by 7.63% to $2.6 million in 2022, then soared by 900.18% to $26.2 million in 2023, then surged by 35.14% to $35.3 million in 2024, then climbed by 29.29% to $45.7 million in 2025.
- Business Quant data shows OCS's Shares Outstanding (Entity) at $45.7 million in Q4 2025, $45.8 million in Q3 2025, and $45.7 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Oculis Holding AG | 635.01 Mn | 346.13 Mn | - | 52.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.24 Mn |
| Mar 31, 2026 | 52.24 Mn |
| Dec 31, 2025 | 52.24 Mn |
| Sep 30, 2025 | 40.41 Mn |
| Jun 30, 2025 | 40.41 Mn |
| Mar 31, 2025 | 40.41 Mn |
| Dec 31, 2024 | 40.41 Mn |
| Sep 30, 2024 | 29.90 Mn |
| Jun 30, 2024 | 29.90 Mn |
| Mar 31, 2024 | 29.90 Mn |
| Dec 31, 2023 | 29.90 Mn |
| Sep 30, 2023 | 3.41 Mn |
| Jun 30, 2023 | 3.41 Mn |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 3.41 Mn |
| Jun 30, 2022 | 3.41 Mn |
| Dec 31, 2021 | 3.41 Mn |
| Dec 31, 2020 | 2.58 Mn |